ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) and Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.
Institutional and Insider Ownership
68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares ARS Pharmaceuticals and Sunshine Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ARS Pharmaceuticals | -184.24% | -256.67% | -69.63% |
| Sunshine Biopharma | -17.94% | -26.36% | -20.60% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ARS Pharmaceuticals | $84.28 million | 4.87 | -$171.30 million | ($2.18) | -1.89 |
| Sunshine Biopharma | $36.31 million | 0.10 | -$5.97 million | ($10.15) | -0.08 |
Sunshine Biopharma has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
ARS Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for ARS Pharmaceuticals and Sunshine Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| Sunshine Biopharma | 1 | 1 | 1 | 0 | 2.00 |
ARS Pharmaceuticals presently has a consensus price target of $25.00, suggesting a potential upside of 506.06%. Sunshine Biopharma has a consensus price target of $70.00, suggesting a potential upside of 8,617.31%. Given Sunshine Biopharma’s higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than ARS Pharmaceuticals.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
